TERN-701
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Myeloid Leukemia, Chronic Phase
Conditions
Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
Trial Timeline
Mar 26, 2024 → May 31, 2030
NCT ID
NCT06163430About TERN-701
TERN-701 is a phase 1/2 stage product being developed by Terns Pharmaceuticals for Chronic Myeloid Leukemia, Chronic Phase. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06163430. Target conditions include Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06163430 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Chronic Myeloid Leukemia, Chronic Phase